News
The genome incorporation mechanism for LINE-1, the only autonomously active retrotransposon in humans, leverages the cell ...
Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback